论文部分内容阅读
目的：观察小剂量血脂康、普伐他汀对高血脂病人的长期调脂作用。方法：多中心，195例高血脂病人，分血脂康组每晚睡前口服血脂康2粒（含他汀类物质6mg）与普伐他汀组（每晚睡前口服5mg）治疗6个月，比较治疗前、后血脂水平变化及两组间差异，用方差分析法检验及X2检验。结果：血脂康与普伐他汀治疗6个月时，TC下降16%及17%，TG下降13%及15%，LDL下降23%及21%；HDL在血脂康组上升2%，在普伐他汀组上升10%。两组均能有效降低LDL/HDL。两组间比较普伐他汀升HDL作用较血脂康稍好（P=0.05）。两组TC、LDL、LDL/HDL下降均有统计学意义。两组TG下降及HDL升高无统计学意义，血脂康及普伐他汀组降TC疗效分别为54.6%、68.4%；升HDL疗效分别为49.1%、53.9%；降TG为46.2%、40.8%。两组疗效差异均无显著性。两组均未见严重副作用。结论：小剂量他汀类药物（如血脂康和普伐他汀）长期口服治疗成人血脂紊乱，安全、有效。
Objective: To observe the long-term lipid-lowering effect of low-dose Xuezhikang and pravastatin on hyperlipidemia patients. Methods: A multicenter, 195 patients with hyperlipidemia were randomly divided into two groups. Each group was given Xuezhikang 2 tablets (containing 6 mg statin) and pravastatin group (5 mg orally before going to bed every night) before going to bed every night for 6 months. Before and after treatment, blood lipid levels and differences between the two groups, with analysis of variance test and X2 test. Results: At 6 months of treatment with Xuezhikang and pravastatin, TC decreased by 16% and 17%, TG decreased by 13% and 15%, LDL decreased by 23% and 21%, HDL increased by 2% in Xuezhikang group, Statin group increased by 10%. Both groups were effective in lowering LDL / HDL. The effect of pravastatin-induced HDL between the two groups was slightly better than that of Xuezhikang (P = 0.05). Two groups of TC, LDL, LDL / HDL decreased statistically significant. The decrease of TG and the increase of HDL in two groups were not statistically significant. The reduction of TC in Xuezhikang and pravastatin group was 54.6% and 68.4% respectively; the effect of increasing HDL was 49.1% and 53.9% respectively; the lowering TG was 46.2% and 40.8% . No significant difference between the two groups. No serious side effects were seen in either group. Conclusion: Long-term oral administration of low-dose statins (such as Xuezhikang and pravastatin) for the treatment of dyslipidemia in adults is safe and effective.